RxDoctor Payments DataLook up a doctor →

Matias Valsecchi, MD

Hematology & Oncology · Huntington, WVNPI 1235338328

Payments from drug & device makers

$17,244in general payments, 2019–2025

Across 926 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Genentech USA, Inc.$778
  • Merck$767
  • plus $10K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis122$1,857
E.r. Squibb & Sons, L.L.C.96$1,352
Pfizer68$1,122
AstraZeneca(2 entities)32$1,048
Genentech USA, Inc.39$778
Merck41$767
Bristol Myers Squibb32$695
Daiichi Sankyo Inc.51$686
Seagen Inc.30$673
Johnson & Johnson(2 entities)41$645
Astellas Pharma US Inc28$577
Incyte Corporation20$552
Amgen22$525
GSK21$492
AbbVie24$445
Pharmacyclics LLC, An Abbvie Company16$316
Ipsen Biopharmaceuticals, Inc15$289
Sanofi14$280
Takeda Pharmaceuticals U.S.A., Inc.8$219
EMD Serono, Inc.11$210
Beigene USA, Inc.7$200
Array Biopharma Inc11$191
Coherus Oncology, Inc.4$178
Jazz Pharmaceuticals Inc.9$170
Taiho Oncology, Inc.7$157
Lilly USA, LLC10$156
Bayer9$140
Tersera Therapeutics LLC5$140
Karyopharm Therapeutics Inc.7$137
AVEO Pharmaceuticals, Inc.8$127
Puma Biotechnology, Inc.8$122
Eisai Inc.6$122
Morphosys, US Inc.5$111
Exelixis Inc.5$105
Mirati Therapeutics, Inc.5$99
Tempus AI, Inc5$95
Gilead(2 entities)5$81
Novocure Inc.5$78
Kyowa Kirin, Inc.4$71
Blueprint Medicines Corporation4$67
ADC Therapeutics America, Inc.4$61
Boehringer Ingelheim4$60
Alnylam Pharmaceuticals Inc.3$56
Stemline Therapeutics Inc.3$54
Rigel Pharmaceuticals, Inc.4$54
Dova Pharmaceuticals4$53
Beone Medicines USA, Inc.2$47
Clovis Oncology, Inc.3$45
TG Therapeutics, Inc.2$43
Geron Corporation1$39
Tesaro, Inc.2$39
Galvanize Therapeutics, Inc2$37
Agios Pharmaceuticals, Inc.2$34
Caris MPI, Inc.1$33
Regeneron Healthcare Solutions, Inc.2$31
Foundation Medicine, Inc.2$31
Adaptive Biotechnologies Corporation1$29
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$28
Recordati_rare_diseases_inc.1$28
Cumberland Pharmaceuticals, Inc.1$28

How this compares

$17,244 in reported general payments places this provider in the 70th percentile of 72 hematology & oncology providers in West Virginia.

See all hematology & oncology providers in West Virginia →

Medicare billing

Part B allowed, 2024
$156,179
Medicare patients
459
Services billed
1,781

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Huntington

See the full list for West Virginia →

Where these figures come from

Is this you, or does something look wrong? →